Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.

"CONFLICT OF INTEREST STATEMENT P.M., J.A.D. and P.D.G. are employees of Health Economics and Outcomes Research Ltd, Cardiff, UK. Health Economics and Outcomes Research Ltd received fees from AstraZeneca in relation to this study. D.C.W. provided ongoing consultancy services to AstraZeneca in the last 2 years and has received honoraria and/or consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, Eledon, Galderma, Gilead, GlaxoSmithKline, George Clinical, Janssen, Merck Sharp and Dohme, ProKidney, Takeda, Vifor and Zydus. He also reports speaking fees from Astellas, AstraZeneca and Vifor, and support for travel/meeting attendance from Astellas, AstraZeneca and Pro. He has served on DSMBs for Eledon, Galderma, Merck, ProKidney and Pathalys. He is a member of the International Society of Nephrology and National Institute of Health Research, UK. P.R. has received honoraria to Steno Diabetes Center Copenhagen for consultancy from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Gilead, Novo Nordisk, Merck, Mundipharma, Sanofi and Vifor, and research support from AstraZeneca, Bayer and Novo Nordisk. G.M.C. received fees from AstraZeneca for service on the DAPA-CKD trial steering committee. He serves on the Board of Directors for Satellite Healthcare, a non-profit dialysis provider. He has received research grants to his institution from NIDDK, NIAID and CSL Behring. He has served on trial-steering committees with Akebia, AstraZeneca, Gilead, Sanifit and Vertex. He has served as an advisor to Applaud, Ardelyx, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset, Renibus, Unicycive and Vertex. He has served on DSMBs for NIDDK, Bayer, Mineralys and ReCor. He also declares stock or stock options for Applaud, Ardelyx, CloudCath, Durect, Eliaz Therapeutics, Miromatrix, Outset and Renibus. R.C.-R. has received honoraria as consultant from AstraZeneca, Boehringer Ingelheim, Bayer, Chinook, AbbVie and Novo Nordisk, and research support from AstraZeneca, Boehringer Ingelheim, Roche and Novo Nordisk. He has received speaking fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Amgen. K.T. has honoraria as lecture fee from Novartis, AstraZeneca, Ono, Daiichi-Sankyo, Takeda, Otsuka, Bayer and Kyowa-Kirin. He has received research support from AstraZeneca, Ono, Bayer, Kyowa-Kirin, Otsuka, Takeda and Daiichi-Sankyo. S.B. and J.J.G.S. are employees of AstraZeneca."

"FUNDING This work and its publication were funded by AstraZeneca. Author independence in study design, data interpretation, manuscript preparation for publication was ensured by the funding agreement."